
## Paul C Dinh

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7293528/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Escherichia coli Isolates That Carry <i>vat</i> , <i>fyuA</i> , <i>chuA</i> , and <i>yfcV</i> Efficiently Colonize the Urinary Tract. Infection and Immunity, 2012, 80, 4115-4122.	2.2	226
2	Toxicities Associated with Cisplatin-Based Chemotherapy and Radiotherapy in Long-Term Testicular Cancer Survivors. Advances in Urology, 2018, 2018, 1-20.	1.3	81
3	Genetic and Modifiable Risk Factors Contributing to Cisplatin-induced Toxicities. Clinical Cancer Research, 2019, 25, 1147-1155.	7.0	72
4	Testicular Cancer Survivorship. Journal of the National Comprehensive Cancer Network: JNCCN, 2019, 17, 1557-1568.	4.9	42
5	The association between sleep duration and lipid profiles: the NHANES 2013–2014. Journal of Diabetes and Metabolic Disorders, 2019, 18, 315-322.	1.9	28
6	Clinical and Genome-wide Analysis of Cisplatin-induced Tinnitus Implicates Novel Ototoxic Mechanisms. Clinical Cancer Research, 2019, 25, 4104-4116.	7.0	27
7	Association of Iodine and Iron with Thyroid Function. Biological Trace Element Research, 2017, 179, 38-44.	3.5	24
8	Clinical and Genetic Risk Factors for Adverse Metabolic Outcomes in North American Testicular Cancer Survivors. Journal of the National Comprehensive Cancer Network: JNCCN, 2018, 16, 257-265.	4.9	24
9	Associations of leptin and adiponectin with incident type 2 diabetes and interactions among African Americans: the Jackson heart study. BMC Endocrine Disorders, 2020, 20, 31.	2.2	21
10	Smoking cessation, weight gain, and risk of stroke among postmenopausal women. Preventive Medicine, 2019, 118, 184-190.	3.4	17
11	Clinical and Genome-Wide Analysis of Serum Platinum Levels after Cisplatin-Based Chemotherapy. Clinical Cancer Research, 2019, 25, 5913-5924.	7.0	16
12	Pharmacogenomics of <scp>cisplatinâ€induced</scp> neurotoxicities: Hearing loss, tinnitus, and peripheral sensory neuropathy. Cancer Medicine, 2022, 11, 2801-2816.	2.8	14
13	Adverse Health Outcomes in Relationship to Hypogonadism After Chemotherapy: A Multicenter Study of Testicular Cancer Survivors. Journal of the National Comprehensive Cancer Network: JNCCN, 2019, 17, 459-468.	4.9	13
14	Ototoxicity After Cisplatin-Based Chemotherapy: Factors Associated With Discrepancies Between Patient-Reported Outcomes and Audiometric Assessments. Ear and Hearing, 2022, 43, 794-807.	2.1	13
15	Adverse Health Outcomes Among US Testicular Cancer Survivors After Cisplatin-Based Chemotherapy vs Surgical Management. JNCI Cancer Spectrum, 2020, 4, pkz079.	2.9	12
16	Solid and Hematologic Neoplasms After Testicular Cancer: A US Population-Based Study of 24 900 Survivors. JNCI Cancer Spectrum, 2020, 4, pkaa017.	2.9	12
17	Relationship of Cisplatin-Related Adverse Health Outcomes With Disability and Unemployment Among Testicular Cancer Survivors. JNCI Cancer Spectrum, 2020, 4, pkaa022.	2.9	11
18	Physical activity and weight gain after smoking cessation in postmenopausal women. Menopause, 2019, 26, 16-23.	2.0	5

PAUL C DINH

#	Article	IF	CITATIONS
19	Adverse health outcomes in relationship to hypogonadism (HG) after platinum-based chemotherapy: A multicenter study of North American testicular cancer survivors (TCS) Journal of Clinical Oncology, 2017, 35, LBA10012-LBA10012.	1.6	5
20	Personality traits and the risk of coronary heart disease or stroke in women with diabetes – an epidemiological study based on the Women's Health Initiative. Menopause, 2019, Publish Ahead of Print, 1117-1124.	2.0	4
21	The role of reproductive coercion in women's risk for HIV: A caseâ€control study of outpatients in Gauteng, South Africa. International Journal of Gynecology and Obstetrics, 2020, 151, 377-382.	2.3	4
22	Lifestyle and Psychosocial Patterns and Diabetes Incidence Among Women with and Without Obesity: a Prospective Latent Class Analysis. Prevention Science, 2020, 21, 850-860.	2.6	4
23	Use of Medications for Treating Anxiety or Depression among Testicular Cancer Survivors: A Multi-Institutional Study. Cancer Epidemiology Biomarkers and Prevention, 2021, 30, 1129-1138.	2.5	4
24	Risk Patterns and Mortality in Postmenopausal Women Using Latent Class Analysis. American Journal of Preventive Medicine, 2021, 61, e225-e233.	3.0	4
25	Cisplatin, environmental metals, and cardiovascular disease: an urgent need to understand underlying mechanisms. Cardio-Oncology, 2021, 7, 34.	1.7	4
26	Associations of adiponectin and leptin with brain natriuretic peptide in African Americans: the Jackson Heart Study. Cardiovascular Endocrinology and Metabolism, 2020, 9, 49-55.	1.1	3
27	Factors associated with use of medications for anxiety and depression in testicular cancer survivors after cisplatin-based chemotherapy Journal of Clinical Oncology, 2021, 39, 5025-5025.	1.6	2
28	Associations of Body Fat Distribution and Cardiometabolic Risk of Testicular Cancer Survivors after Cisplatin-Based Chemotherapy. JNCI Cancer Spectrum, 0, , .	2.9	2
29	Hearing loss after cisplatin-based chemotherapy: Patient-reported outcomes versus audiometric assessments Journal of Clinical Oncology, 2021, 39, 5016-5016.	1.6	1
30	Integration of a polygenic risk score of kidney function with cumulative cisplatin dose and time variables for the prediction of serum platinum levels Journal of Clinical Oncology, 2021, 39, 12063-12063.	1.6	1
31	Adverse health outcomes in relationship to hypogonadism (HG) after platinum-based chemotherapy: A multicenter study of North American testicular cancer survivors (TCS) Journal of Clinical Oncology, 2017, 35, LBA10012-LBA10012.	1.6	1
32	Second solid (SMN) and hematologic malignant neoplasms (HMN) among 24,900 United States testicular cancer survivors (TCS) after chemotherapy (CHEM), radiotherapy (RT), or surgery only (SURG) Journal of Clinical Oncology, 2019, 37, 11573-11573.	1.6	1
33	Re: Thyroid hypofunction in aging testicular cancer survivors. Acta OncolÃ <sup>3</sup> gica, 2022, 61, 386-387.	1.8	1
34	Epigenetic age acceleration in U.S. testicular cancer survivors (TCS) Journal of Clinical Oncology, 2022, 40, 5033-5033.	1.6	1
35	Increased Risk of Cardiovascular Sequelae in Survivors of Male Germ Cell Cancer. Journal of Clinical Oncology, 2020, 38, 1497-1498.	1.6	0
36	Pharmacogenomics of cisplatin-induced neurotoxicities: Hearing loss, tinnitus and peripheral sensory neuropathy Journal of Clinical Oncology, 2021, 39, 12004-12004.	1.6	0

PAUL C DINH

#	Article	IF	CITATIONS
37	Effect of pretreatment central adiposity on the cardiometabolic risk of male germ cell tumor survivors after cisplatin-based chemotherapy Journal of Clinical Oncology, 2021, 39, 5019-5019.	1.6	Ο
38	Pharmacokinetic (PK) modeling of serum platinum to reveal extent of long-term exposure and associated comorbidities after cisplatin treatment Journal of Clinical Oncology, 2018, 36, 10058-10058.	1.6	0
39	Impact of cisplatin-related adverse health outcomes (AHOs) on employment outcomes and self-reported health (SRH) among testicular cancer survivors (TCS) Journal of Clinical Oncology, 2019, 37, e16058-e16058.	1.6	0
40	Impact of adverse health outcomes (AHOs) on self-reported physical and mental health in U.S. testicular cancer survivors (TCS) Journal of Clinical Oncology, 2022, 40, 12080-12080.	1.6	0
41	Cisplatin-induced tinnitus (CIS-TINN) and patient-reported outcomes in adult-onset cancer survivors Journal of Clinical Oncology, 2022, 40, e24089-e24089.	1.6	0
42	Building a model to predict the risk of multiple severe neurotoxicities in cancer survivors after cisplatin treatment Journal of Clinical Oncology, 2022, 40, e24066-e24066.	1.6	0
43	Impact of cisplatin-induced hearing loss (CIHL) on patient-reported social and emotional functioning Journal of Clinical Oncology, 2022, 40, 12120-12120.	1.6	0